A BILL 
To prohibit the President from taking any action to support 
the waiver of obligations of members of the World Trade 
Organization under the Agreement on Trade-Related As-
pects of Intellectual Property Rights in relation to the 
prevention, containment, mitigation, or treatment of 
COVID–19 unless a statute is enacted expressly author-
izing such a waiver with respect to the prevention, con-
tainment, mitigation, or treatment of COVID–19, and 
for other purposes. 
20:32 Jun 17, 2021
H3236
lotter on DSK11XQN23PROD with BILLS
2 
•HR 3236 IH
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘American Medical In-
4
vestment Generating Overseas Security Act’’ or the ‘‘AMI-
5
GOS Act’’. 
6
SEC. 2. PROHIBITION ON ACTION TO SUPPORT WAIVER OF 
7
OBLIGATIONS OF WTO MEMBERS UNDER THE 
8
TRIPS AGREEMENT IN RELATION TO THE 
9
PREVENTION, CONTAINMENT, MITIGATION, 
10
OR TREATMENT OF COVID–19. 
11
The President may not take any action to support 
12
the waiver of obligations of members of the World Trade 
13
Organization under the TRIPS Agreement to implement 
14
or apply sections 1, 4, 5, and 7 of part II of the TRIPS 
15
Agreement or to enforce such sections under part III of 
16
the TRIPS Agreement in relation to the prevention, con-
17
tainment, mitigation, or treatment of COVID–19 unless 
18
a statute is enacted expressly authorizing such a waiver 
19
with respect to the prevention, containment, mitigation, 
20
or treatment of COVID–19. 
21
SEC. 3. PRIORITY IN ALLOCATING EXCESS VACCINES FOR 
22
COVID–19 TO OTHER COUNTRIES. 
23
(a) IN
GENERAL.—In allocating vaccines for 
24
COVID–19 that are procured by or otherwise subject to 
25
20:32 Jun 17, 2021
H3236
lotter on DSK11XQN23PROD with BILLS
3 
•HR 3236 IH
the control of the Federal Government and in excess of 
1
the demand for such vaccines by individuals in the United 
2
States who are eligible to receive such vaccines, the Presi-
3
dent shall allocate such vaccines in accordance with the 
4
following order of priority: 
5
(1) First, to other countries in the Western 
6
Hemisphere with the lowest rates of immunization 
7
for COVID–19. 
8
(2) Second, to other countries in the Western 
9
Hemisphere based on other metrics developed by the 
10
President. 
11
(3) Third, to United States allies and partner 
12
countries with the lowest rates of immunization for 
13
COVID–19. 
14
(4) Fourth, to United States allies and partner 
15
countries based on the metrics developed under 
16
paragraph (2). 
17
(b) EXCEPTIONS.—In allocating vaccines described in 
18
subsection (a), the President may waive the prioritization 
19
otherwise required by such subsection to allocate such vac-
20
cines to countries that are determined by the President 
21
to be— 
22
(1) experiencing a significantly high number of 
23
per capita COVID–19 cases and associated hos-
24
pitalizations; 
25
20:32 Jun 17, 2021
H3236
lotter on DSK11XQN23PROD with BILLS
4 
•HR 3236 IH
(2) at risk of a country-wide health care system 
1
collapse as a result of COVID–19; or 
2
(3) experiencing the spread of a variant of 
3
SARS–CoV–2 that needs to be contained. 
4
(c) MONITORING.—The President shall monitor the 
5
allocation of vaccines for COVID–19 to foreign countries 
6
under this section to ensure the governments of such coun-
7
tries provide such vaccines to the peoples of such countries 
8
in a timely manner and do not otherwise withhold such 
9
vaccines. 
10
SEC. 4. MARKING REQUIREMENTS. 
11
(a) IN GENERAL.—Except as provided in subsection 
12
(b), vaccines for COVID–19 provided to foreign countries 
13
under section 3 shall be marked as assistance from the 
14
American people or the United States Government and 
15
shall include a depiction of the flag of the United States 
16
if appropriate. 
17
(b) EXCEPTION.—The marking requirements of sub-
18
section (a) shall not apply if the President determines that 
19
such requirements will endanger the lives or safety of per-
20
sons delivering such vaccines or would have an adverse ef-
21
fect on the administration of such vaccines. 
22
SEC. 5. DEFINITIONS. 
23
In this Act: 
24
20:32 Jun 17, 2021
H3236
lotter on DSK11XQN23PROD with BILLS
5 
•HR 3236 IH
(1) COVID–19.—The term ‘‘COVID–19’’ re-
1
fers to the 2019 coronavirus disease caused by 
2
SARS–CoV–2. 
3
(2) SARS–CoV–2.—The term ‘‘SARS–CoV–2’’ 
4
refers to the severe acute respiratory syndrome 
5
coronavirus 2 virus responsible for COVID–19 and 
6
includes any viral variant mutating therefrom with 
7
pandemic potential. 
8
(3) TRIPS AGREEMENT.—The term ‘‘TRIPS 
9
Agreement’’ means the Agreement on Trade-Related 
10
Aspects of Intellectual Property Rights referred to in 
11
section 101(d)(15) of the Uruguay Round Agree-
12
ments Act (19 U.S.C. 3511(d)(15)). 
13
Æ 
20:32 Jun 17, 2021
H3236
lotter on DSK11XQN23PROD with BILLS
